

18 Dec 2016 | Opinion

Top Alliance Of 2016: Cast Your Vote!

by Nancy Dvorin

It's time once again for *In Vivo's Deal of the Year* contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to [pick the winners](#). (It's free.)

In Vivo's Top Alliance Of 2016 – The Nominees Are:

Synthetic Bio Tie-Up: Synlogic received big pharma validation of its technology in early February, signing its first-ever partnership, a multiyear collaboration with AbbVie to develop "synthetic biotic" therapies for Crohn's disease and ulcerative colitis. [\[See Deal\]](#)

Cigna Pays If PCSK9s Perform: In May, Cigna signed value-based contracts with Amgen and Sanofi/Regeneron for their cholesterol-lowering drugs Repatha and Praluent. The drugmakers will discount the products more steeply if LDL levels don't drop.

Verily We Roll Along: Google-owned Verily Life Sciences formed diabetes and neuromodulation joint ventures with big pharmas GlaxoSmithKline (August) and Sanofi (September). [\[See Deal\]](#)[\[See Deal\]](#)

AZ Drops Assets: In October, AstraZeneca completed five out-licensing deals cumulatively worth more than \$1 billion, the busiest month by far in its year-long purge of non-core assets. [\[See Deal\]](#)[\[See Deal\]](#)[\[See Deal\]](#)[\[See Deal\]](#)[\[See Deal\]](#)

Bayer Buys Into Gene Editing: In August, Bayer and CRISPR Therapeutics unveiled their \$335 million joint venture Casebia Therapeutics, which will use CRISPR's gene editing technology to develop drugs for blood disorders, blindness and congenital heart disease.



IN VIVO

CITELINE COMMERCIAL

[CLICK HERE Here To Cast Your Vote For The Most Significant Strategic Alliance Of 2016](#)

Coming Up Next In IVDOTY16: Top Financing And Top M&A
